Carboplatin/paclitaxel

Carboplatin/paclitaxel Reactions 1680, p83 - 2 Dec 2017 Febrile neutropenia, neuropathy and anorexia: 3 case reports In a retrospective study of 52 patients, three patients [ages and sexes not stated] were described, who developed febrile neutropenia, neuropathy or anorexia during treatment with carboplatin and paclitaxel [durations of treatment to reactions onsets and outcomes not stated]. Patient 1: a patient developed febrile neutropenia during treatment with carboplatin and paclitaxel. The patient, who had progression of urothelial carcinoma after gemcitabine and cisplatin chemotherapy, received IV infusion of carboplatin AUC 5 and IV infusion of paclitaxel 175 mg/m on day 1. The cycle was repeated every 21 days. Subsequently, the patient developed grade 3 febrile neutropenia. Patient 2: a patient developed neuropathy during treatment with carboplatin and paclitaxel. The patient, who had progression of urothelial carcinoma after gemcitabine and cisplatin chemotherapy, received IV infusion of carboplatin AUC 5 and IV infusion of paclitaxel 175 mg/m on day 1. The cycle was repeated every 21 days. Subsequently, the patient developed grade 3 neuropathy. Patient 3: a patient developed anorexia during treatment with carboplatin and paclitaxel. The patient, who had progression of urothelial carcinoma after gemcitabine and cisplatin chemotherapy, received IV infusion of carboplatin AUC 5 and IV infusion of paclitaxel 175 mg/m on day 1. The cycle was repeated every 21 days. Subsequently, the patient developed grade 3 anorexia. Author comment: "Table IV shows the toxicities associated with [paclitaxel and carboplatin] chemotherapy." "[F]ebrile neutropenia was only observed in 1 patient". "With regard to non-hematological toxicities, grade 3 neuropathy and grade 3 anorexia developed in 1 patient each." Furubayashi N, et al. The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy. Molecular and Clinical Oncology 7: 1112-1118, No. 6, Dec 2017. Available from: URL: http:// doi.org/10.3892/mco.2017.1452 - Japan 803284418 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Carboplatin/paclitaxel

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/carboplatin-paclitaxel-09hJZU3GL7
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39014-x
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p83 - 2 Dec 2017 Febrile neutropenia, neuropathy and anorexia: 3 case reports In a retrospective study of 52 patients, three patients [ages and sexes not stated] were described, who developed febrile neutropenia, neuropathy or anorexia during treatment with carboplatin and paclitaxel [durations of treatment to reactions onsets and outcomes not stated]. Patient 1: a patient developed febrile neutropenia during treatment with carboplatin and paclitaxel. The patient, who had progression of urothelial carcinoma after gemcitabine and cisplatin chemotherapy, received IV infusion of carboplatin AUC 5 and IV infusion of paclitaxel 175 mg/m on day 1. The cycle was repeated every 21 days. Subsequently, the patient developed grade 3 febrile neutropenia. Patient 2: a patient developed neuropathy during treatment with carboplatin and paclitaxel. The patient, who had progression of urothelial carcinoma after gemcitabine and cisplatin chemotherapy, received IV infusion of carboplatin AUC 5 and IV infusion of paclitaxel 175 mg/m on day 1. The cycle was repeated every 21 days. Subsequently, the patient developed grade 3 neuropathy. Patient 3: a patient developed anorexia during treatment with carboplatin and paclitaxel. The patient, who had progression of urothelial carcinoma after gemcitabine and cisplatin chemotherapy, received IV infusion of carboplatin AUC 5 and IV infusion of paclitaxel 175 mg/m on day 1. The cycle was repeated every 21 days. Subsequently, the patient developed grade 3 anorexia. Author comment: "Table IV shows the toxicities associated with [paclitaxel and carboplatin] chemotherapy." "[F]ebrile neutropenia was only observed in 1 patient". "With regard to non-hematological toxicities, grade 3 neuropathy and grade 3 anorexia developed in 1 patient each." Furubayashi N, et al. The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy. Molecular and Clinical Oncology 7: 1112-1118, No. 6, Dec 2017. Available from: URL: http:// doi.org/10.3892/mco.2017.1452 - Japan 803284418 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off